P2 Receptor

P2X receptors, which are ligand-gated ion channels, are freely permeable to the three most important physiological cations: sodium, potassium, and calcium. P2X receptors open in the presence of extracellular adenosine triphosphate (ATP) and play an important role in regulating the homeostasis of a range of organisms. P2X receptors are generally classified as ligand-gated cation channels because most of their physiological effects result from the inward flow of cations across the cell surface membrane. The ATP binding site of P2X receptors resides at the interface of neighboring subunits of the multimeric receptor complex.

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S4079 Ticagrelor Ticagrelor (AZD6140, AR-C 126532XX) is the first reversibly binding oral P2Y12 receptor antagonist with Ki of 2 nM.
J Immunother Cancer, 2024, 12(11)e009805
Evid Based Complement Alternat Med, 2022, 2022:7941039
Am J Respir Crit Care Med, 2021, 10.1164/rccm.202009-3686OC
Verified customer review of Ticagrelor
S7705 A-438079 Hydrochloride A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Redox Biol, 2024, 72:103154
Cells, 2023, 12(23)2696
Biomol Biomed, 2023, 23(5):825-837
E1128 BzATP triethylammonium salt BzATP triethylammonium salt acts as a P2X receptor agonist with pEC50s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively, also is potent at P2X7 receptors with EC50s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively.
S1415 Clopidogrel (SR-25990C) Bisulfate Clopidogrel (SR-25990C) Bisulfate is an oral, thienopyridine class antiplatelet agent.
Nat Commun, 2025, 16(1):7974
J Immunother Cancer, 2024, 12(11)e009805
Cell Mol Life Sci, 2024, 81(1):116
Verified customer review of Clopidogrel (SR-25990C) Bisulfate
S8725 A-804598 A-804598 is a selective P2X7R antagonist with high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.
Immunobiology, 2025, 230(6):153119
Biol Pharm Bull, 2025, 48(5):657-671
J Cell Physiol, 2022, 10.1002/jcp.30685
S3737 Cangrelor Tetrasodium Cangrelor (AR-C69931MX) is a potent, competitive P2Y12 receptor inhibitor that is administered by intravenous infusion and rapidly achieves near complete inhibition of ADP-induced platelet aggregation.
J Immunother Cancer, 2024, 12(11)e009805
J Thromb Haemost, 2023, S1538-7836(23)00082-X
Food Funct, 2021, 10.1039/d1fo00531f
S1258 Prasugrel Prasugrel (Effient, Efient, Prasita,CS-747, LY640315,PCR 4099) is a thienopyridine ADP receptor (P2Y12) antagonist, used for the reduction of thrombotic cardiovascular events.
Oncol Lett, 2018, 15(5):6107-6114
J Toxicol Sci, 2017, 42(6):755-761
S2855 MRS 2578 MRS2578 is a potent P2Y6 receptor antagonist with an IC50 of 37 nM, and exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
Ann Med, 2022, 54(1):1616-1626
Sci Rep, 2021, 11(1):15129
S0826 A-740003 A-740003 is a potent, selective and competitive antagonist of P2X7 receptor with IC50 of 18 nM and 40 nM for rat and human P2X7 receptors, respectively. This compound potently blocks agonist-evoked IL-1β release and pore formation with IC50 of 156 nM and 92 nM in differentiated human THP-1 cells.
Am J Cancer Res, 2024, 14(2):585-600
Cell Rep, 2023, 42(7):112696
S4637 Prasugrel Hydrochloride Prasugrel hydrochloride (Prasugrel HCl, LY640315, PCR 4099 Hydrochloride) is a piperazine derivative and platelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.
J Immunother Cancer, 2024, 12(11)e009805
Oncol Lett, 2018, 15(5):6107-6114